This article reviews recent changes in the design of HIV-I vaccine. The safety information for current vaccines has been established, and future ethical considerations are reviewed. Of recent significance, gp120 envelope vaccines are being combined with canarypox vectors in an effort to elicit a broad immune response. This will probably be the aim of future research for an ever-growing problem. A total of 10 143 AIDS cases have occurred in the USA in the year 2000.(1) The international burden is grimmer. For example, approximately 13% of South Africans between 20 and 64 years old are HIV positive. Predictions estimate this number to rise to almost 30% by 2010.(2) With many different HIV serotypes, a worldwide effective HIV vaccine is not in the near future.(3) However, the scientific community has bolstered its effort by strengthening resources and developing national and international collaboration groups focused in developing a safe and effective HIV vaccine.